Colorado, Maryland Drug Price Boards Inch Closer to Payment Caps

States considering whether to enact prescription drug affordability boards have their eyes on panels in Colorado and Maryland as they move closer toward enacting their first-ever limits on what health plans pay for some of the nation’s priciest drugs.

The Colorado Prescription Drug Affordability Board is scheduled to meet in October as it considers how to establish limits on how much health plans in the state can pay for three anti-inflammatory treatments: Amgen Inc.‘s Enbrel, Johnson & Johnson‘s Stelara, and Novartis AG‘s Cosentyx.

Maryland’s board hopes to complete affordability reviews by the end of the year for ...